On May 19, 2020, Bio-Techne and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences, announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System and Renalytix AI formed exclusively to ensure that diagnostic tests for critical health challenges are accessible to all.